This is also Sun Pharma's second acquisition in less than three months and comes as the company looks to size up its specialty therapy portfolio.

Adenocarcinoma grows in the tissue of the prostate gland, but other types of cancer can also start in the prostate or spread ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun ...

Sun Pharma has made its play just three months after Checkpoint won FDA approval for PD-L1 inhibitor Unloxcyt (cosibelimab) ...

New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

A research team led by Prof. JIANG Yanyi from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, ...

The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...